Significance of meningococcal hyperinvasive clonal complexes and their influence on vaccines development

• Autorzy: Wasko I. , Hryniewicz W. , Skoczynska A.
• Języki publikacji: EN

Abstrakty

EN

Neisseria meningitidis is a commensal of human nasopharynx and humans are the only known reservoir and host of this bacterium. It is also known as a dangerous and devastating pathogen, and infection with N. meningitidis may lead to rapidly progressing septicemia or meningitis. These severe infections, called invasive meningococcal disease (IMD), are one of the major public health threats worldwide. IMD may occur sporadically, but also in outbreaks, epidemics, and pandemics. Most of the IMD cases in the world are caused by isolates of genetically related groups, clonal complexes (CC), including those with special epidemiological significance called hyperinvasive clonal complexes. It is still unknown why some of them may persist for decades, whereas other are quickly replaced and disappear. As a consequence, the epidemiological situation of IMD is variable worldwide and greatly depends on the emergence and widespread of clones belonging to hyperinvasive clonal complexes. Their occurrence has serious implications for health policy, requiring often mass immunization campaigns. Paradoxically, alarming situations caused by hyperinvasive CCs stimulated the development and introduction of new vaccines against meningococci. Despite the unquestionable success of these vaccines, isolates of hyperinvasive clones constitute a permanent public health threat, because they are constantly circulating and able to modify their antigenic profiles to escape the host immune response. Therefore, continuous monitoring of meningococcal isolates including thorough molecular typing is indispensable and fundamental for taking appropriate preventive measures.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2015
• Tom: 64
• Numer: 4
• Opis fizyczny: p.313-321,fig.,ref.

Twórcy

autor

Wasko I.

• National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland

autor

Hryniewicz W.

• National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland

autor

Skoczynska A.

• National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland

Bibliografia

• Achtman M. 1997. Microevolution and epidemic spread of serogroup A Neisseria meningitidis – a review. Gene 192(1): 135–140.
• Ashton F.E., J.A. Ryan, A. Borczyk, D.A. Caugant, L. Mancino and D. Huang. 1991. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J. Clin. Microbiol. 11: 2489–2493.
• Barra G.N., P.A. Araya, J.O. Fernandez, J.M. Gabastou, J.C. Hormazábal, M. Seoane, P.C. Pidal, M.T. Valenzuela and A.B. IbarzPavón. 2013. Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010–2011. PLoS One 8(6): e66006.
• Barroso D.E., TM. Castiñeiras, A.C. Cabral, A.C Vicente, M.C. Rebelo, E.O. Cerqueira, M.M. Tulenko, J.W. Marsh, M.G. Krauland and L.H. Harrison. 2013. Neisseria meningitidis ST-11clonal complex bearing capsule serogroups B, C, or W in Brazil. J. Infect. 66(6): 547–550.
• Bijlsma M.W., V. Bekker, M.C. Brouwer, L. Spanjaard, D. van de Beek and A. van der Ende. 2014. Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data. Lancet Infect. Dis. 14(9): 805–812.
• Brehony C., K.A. Jolley and M.C Maiden. 2007. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol. Rev. 31(1): 15–26.
• Bröker M., S. Bukovski, D. Culic, S. Jacobsson, M. Koliou, M. Kuusi, M.J. Simões, A. Skoczynska M. Toropainen, M.K. Taha and others. 2014. Meningococcal serogroupY emergence in Europe: high importance in some European regions in 2012. Hum. Vaccin. Immunother. 10(6): 1725–1728.
• Caesar N.M., K.A. Myers and X. Fan. 2013. Neisseria meningitidis serogroup B vaccine development. Microb. Pathog. 57: 33–40.
• Campbell H., R. Borrow, D. Salisbury and E. Miller. 2009. Meningococcal C conjugate vaccine: The experience in England and Wales. Vaccine 27 Suppl 2: B20–9.
• Caron F., I.P. du Châtelet, J.P. Leroy, C. Ruckly, M. Blanchard, N. Bohic, N. Massy, I. Morer, D. Floret, V. Delbos and others. 2011. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis. 11(6): 455–463.
• Caugant D.A and P. Nicolas. 2007. Molecular surveillance of meningococcal meningitis in Africa. Vaccine 25 Suppl 1: A8–11.
• Chacon-Cruz E., L.E. Espinosa-De Los Monteros, S. Navarro-Alvarez, J.L. Aranda-Lozano, M.L. Volker-Soberanes, R.M. Rivas-Landeros, A.A. Alvelais-Arzamendi and JA. Vazquez. 2014. An outbreak of serogroupC (ST-11) meningococcal disease in Tijuana, Mexico. Ther. Adv. Vaccines 2(3): 71–76.
• Daugla D.M., J.P. Gami, K. Gamougam, N. Naibei, L. Mbainadji, M. Narbé, J. Toralta, B. Kodbesse, C. Ngadoua, M.E. Coldiron and others. 2014. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 383(9911): 40–47.
• de Lemos A.P., T.Y. Yara, M.C. Gorla, M.V. de Paiva, A.L. de Souza, M.I. Gonçalves, SC. de Almeida, G.R. do Valle and C.T. Sacchi. 2007. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater SaoPaulo, Brazil. J. Clin. Microbiol. 45(4): 1266–1273.
• Deghmane A.E., I. Parent du Chatelet, M. Szatanik, E. Hong, C. Ruckly, D. Giorgini, D. Lévy-Bruhl, J.M. Alonso and M.K. Taha. 2010. Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J. Infect. Dis. 202(2): 247–250.
• De Wals P., M. Dionne, M. Douville-Fradet, N. Boulianne, J. Drapeau and G. De Serres. 1996. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull. World Health Organ. 74(4): 407–411.
• Djingarey M.H., R. Barry, M. Bonkoungou, S. Tiendrebeogo, R. Sebgo, D. Kandolo, C. Lingani, M.P. Preziosi, P.L. Zuber, W. Perea and others. 2012. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 30 Suppl 2: B40–45.
• ECDC. 2013. Invasive meningococcal disease among men who have sex with men, http://www.ecdc.europa.eu/en/publications/Publications/rapid-risk-assessment-invasive-meningococcal-diseaseamong-MSM.pdf. 2015.01.23.
• EMA. 2013. Summary of opinion (initial authorisation) EMA/CHMP/669278/2012, http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002333/WC500134836.pdf. 2013.07.21
• Fazio C., A. Neri, S. Tonino, A. Carannante, M.G. Caporali, S. Salmaso, P. Mastrantonio and P. Stefanelli. 2009. Characterisation of Neisseria meningitidis C strains causing two clusters in the north of Italy in 2007 and 2008. Euro Surveill. 14(16). pii: 19179
• FDA. 2014. First vaccine approved by FDA to prevent serogroup B meningococcal disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.htm. 2014.10.29.
• FDA. 2015. FDA approves a second vaccine to prevent serogroup B meningococcal disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431370.htm. 2015.01.23.
• Garnier F., M. Courouble, F. Denis and M.C. Ploy. 2011. Emergence of 2 Neisseria meningitidis serogroup C clones in a French county. Diagn. Microbiol. Infect. Dis. 69(3):280–282.
• Gottfredsson M., M.A. Diggle, D.I. Lawrie, H. Erlensdóttir, H. Hardardóttir, K.G. Kristinsson and Sc. Clarke. 2006. Neisseria meningitidis sequence type and risk for death, Iceland. Emerg. Infect. Dis. 12(7): 1066–1073.
• Grecki M. and M. Bienias. 2006. Outbreak of invasive meningococcal disease among soldiers in Skwierzyna, Poland, March 2006. Euro Surveill. 11(7): E060706.4.
• Hahné S.J., S.J. Gray, Jean-François, Aguilera, N.S. Crowcroft, T. Nichols, E.B. Kaczmarski and M.E. Ramsay. 2002. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 359(9306): 582–583.
• Halperin S.A., J.A. Bettinger, B. Greenwood, L.H. Harrison, J. Jelfs, S.N. Ladhani, P. McIntyre, M.E. Ramsay and M.A. Sáfadi. 2012. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30 Suppl 2: B26–36.
• Harrison L.H., C.L. Trotter and M.E. Ramsay. 2009. Global epidemiology of meningococcal disease.Vaccine 27 Suppl 2: B51–63.
• Harrison L.H., K.A. Shutt, S.E. Schmink, J.W. Marsh, B.H. Harcourt, X. Wang, A.M. Whitney, D.S. Stephens, A.A. Cohn, N.E. Messonnier and others. 2010. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccineera – UnitedStates, 2000–2005. J. Infect. Dis. 201(8): 1208–1224.
• Hill D.J., N.J. Griffiths, E. Borodina and M. Virji. 2010. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin. Sci (Lond). 118(9):547–64.
• Holst J., D. Martin, R. Arnold, C.C. Huergo, P. Oster, J. O’Hallahan and E. Rosenqvist. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27 Suppl 2: B3–12.
• Holst J., P. Oster, R. Arnold, M.V. Tatley, L.M. Næss, I.S. Aaberge, Y. Galloway, A. Mc Nicholas, J. O’Hallahan, E. Rosenqvist and others. 2013. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum. Vaccin. Immunother 9(6): 1241–1253.
• Hossain M.J., A. Roca, G.A. Mackenzie, M. Jasseh, M.I. Hossain, S. Muhammad, M. Ahmed, O.D. Chidiebere, N. Malick, S.M. Bilquees and others. 2013. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg. Infect. Dis. 19(9): 1507–1510.
• Jafri R.Z., A. Ali, N.E. Messonnier, C. Tevi-Benissan, D. Durrheim, J. Eskola, F. Fermon, K.P. Klugman, M. Ramsay, S. Sow and others. 2013. Global epidemiology of invasive meningococcal disease. Popul. Health Metr. 11(1): 17.
• Jelfs J., R. Munro, F.E. Ashto and D.A. Caugant. 2000. Genetic characterization of a new variant within the ET-37complex of Neisseria meningitidis associated with outbreaks in various parts of the world. Epidemiol. Infect. 125(2): 285–298.
• Jensen E.S., H.C. Schønheyder, I. Lind, L. Berthelsen, B. Nørgård and H.T. Sørensen. 2003. Neisseria meningitidis phenotypic markers and septicaemia, disease progress and case-fatalityrate of meningococcal disease: a 20-year population-based historical follow-up study in a Danish county. J. Med. Microbiol. 52(Pt 2):173–179.
• Kadłubowski M., I. Waśko., A. Klarowicz and W. Hryniewicz. 2007. Invasive meningococcal disease at a military base In Warsaw, January 2007. Euro Surveill. 12(3): E070301.2.
• Kremastinou J., G. Tzanakaki, A. Kansouzidou, A. Pagalis, V. Danielides, G. Kouppari, E. Lada, P. Kriz, M. Musilek, D.M. Weir and others. 1999. Recent emergence of serogroup C meningococcal disease in Greece. FEMS Immunol. Med. Microbiol. 23(1): 49–55.
• Kriz P., J. Vlckova and M. Bobak. 1995. Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic. Epidemiol. Infect. 115(3): 411–418.
• Krizova P. and M. Musilek.1995. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Cent. Eur. J. Public Health. 3(4):189–194.
• Ladhani S.N., K. Beebeejaun, J. Lucidarme, H. Campbell, S. Gray, E. Kaczmarski, M.E. Ramsay and R. Borrow. 2014. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin. Infect. Dis. 60(4): 578–585.
• Larrauri A., R. Cano, M. García and Sd. Mateo. 2005. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23(32): 4097–4100.
• MacNeil J.R., I. Medah, D. Koussoubé, R.T. Novak, A.C. Cohn, F.V. Diomandé, D. Yelbeogo, J.L. Kambou, T.F. Tarbangdo, R. Ouédraogo-Traoré and others. 2014. Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg. Infect. Dis. 20(3): 394–399.
• Maiden M.C., J.A. Bygraves, E. Feil, G. Morelli, J.E. Russell, R. Urwin, Q. Zhang, J. Zhou, K. Zurth, D.A. Caugant and others. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. USA 95(6): 3140–3145.
• Martin D. and R. McDowell. 2004. The epidemiology of meningococcal disease in New Zealand in 2003. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research (ESR) Limited, Wellington: Ministry of Health. Document available on the Ministry of Health’s Web site: http://www.moh.govt.nz; accessed 27.07.2015
• Mayer L.W., M.W. Reeves, N. Al-Hamdan, C.T. Sacchi, M.K. Taha, G.W. Ajello, S.E. Schmink, C.A. Noble, M.L. Tondella, A.M. Whitney and others. 2002. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135strain but clonal expansion within the electophoretictype-37complex. J. Infect. Dis. 185(11): 1596–1605.
• Miller E., D. Salisbury and M. Ramsay. 2001 .Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl 1:S58–67.
• Nicolas P., G. Norheim, E. Garnotel, S. Djibo and D.A. Caugant. 2005. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequencetype5 (ST-5) and ST-11complexes. J. Clin. Microbiol. 43(10): 5129–5135.
• Novak R.T., JL.Kambou, F.V. Diomandé, T.F. Tarbangdo, R. Ouédraogo-Traoré, L. Sangaré, C. Lingani, S.W. Martin, C. Hatcher, L.W. Mayer and others. 2012. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect. Dis. 12(10): 757–764.
• Panatto D., D Amicizia, P.L. Lai, M.L. Cristina, A. Domnich and R. Gasparini.2013. New versus old meningococcal group B vaccines: how the new ones may benefit infants and toddlers. Indian J. Med. Res. 138(6): 835–846.
• Racloz V.N. and S.J. Luiz. 2010. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect. Dis. 10: 175.
• Read R.C. 2014. Neisseria meningitidis; clones, carriage, and disease. Clin. Microbiol. Infect. 20(5): 391–395
• Rosenstein N.E, B.A. Perkins, D.S. Stephens, T. Popovic and J.M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344(18): 1378–1388.
• Schoen C., L. Kischkies, J. Elias and B.J. Ampattu. 2014. Metabolism and virulence in Neisseria meningitidis. Front. Cell Infect. Microbiol. 4: 114
• Serruto D., M.J. Bottomley, S. Ram, M.M. Giuliani and R. Rappuoli. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.Vaccine 30 Suppl 2: B87–97.
• Simon M.S, D. Weiss and R.M. Gulick. 2013. Invasive meningococcal disease in men who have sex with men. Ann. Intern. Med. 159(4): 300–301.
• Skoczynska A., I. Wasko, A. Kuch, A. Gołebiewska, M. Forys and W. Hryniewicz. 2010. Outbreak of invasive meningococcal disease in Goleniów County, north-west Poland, March 2009. Euro Surveill. 15(34): pii.19646.
• Skoczyńska A., I. Waśko, A. Kuch, M. Kadłubowski, A. Gołębiewska, M. Foryś, M. Markowska, P. Ronkiewicz, K. Wasiak, A. Kozińska and others. 2013. A decade of invasive meningococcal disease surveillance in Poland. PLoS One 8(8):e71375.
• Smith I., D.A. Caugant, E.A. Høiby, T. Wentzel-Larsen and A. Halstensen. 2006. Highcase-fatalityrates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11complexes, 1985–2002. Epidemiol. Infect. 134(6): 1195–1202.
• Stephens D.S., B. Greenwood and P. Brandtzaeg. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369(9580): 2196–2210.
• Stephens D.S. 2009. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 27 Suppl 2: B71–7.
• Swartley J.S., A.A. Marfin, S. Edupuganti, L.J. Liu, P. Cieslak, B. Perkins, J.D. Wenger and D.S. Stephens. 1997. Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 94: 271–276.
• Taha M.K., M. Achtman, J.M. Alonso, B. Greenwood, M. Ramsay, A. Fox, S. Gray and E. Kaczmarski. 2000. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 356(9248): 2159.
• Tribe D.E., A.M. Zaia, J.M. Griffith, P.M. Robinson, H.Y. Li, K.N. Taylor and G.G. Hogg. 2002. Increase in meningococcal disease associated with the emergence of a novel ST-11 variant of serogroup C Neisseria meningitidis in Victoria, Australia, 1999–2000. Epidemiol. Infect. 128(1): 7–14.
• Trotter C.L., A.J. Fox, M.E. Ramsay, F. Sadler, S.J. Gray, R. Mallard and E.B. Kaczmarski. 2002. Fatal outcome from meningococcal disease – an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J. Med. Microbiol. 51(10): 855–860.
• Tsang R.S., C.M. Tsai, P. Zhu, L. Ringuette, M. Lorange and D.K. Law. 2004. Phenotypic and genetic characterization of a uniquevariant of serogroup CET-15meningococci (with the antigenicformulaC:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada. J. Clin. Microbiol. 42(4): 1460–1465.
• Tzeng Y.L. and D.S. Stephens. 2000. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect. 2(6): 687–700.
• Vipond C., R. Care and I.M. Feavers. 2012. History of meningococcal vaccines and their serological correlates of protection. Vaccine 30 Suppl 2: B10–7.
• Vogel U., M.K. Taha, J.A. Vazquez, J. Findlow, H. Claus, P. Stefanelli, D.A. Caugant, P. Kriz, R. Abad, S. Bambini and others. 2013. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect. Dis. 13(5): 416–425.
• Waśko I., A. Skoczyńska and W. Hryniewicz. 2009. Epidemic potential of Neisseria meningitidis, experience of NRCBM (in Polish) Nowa Klinika Vol. 16–17: 751–755.
• Watkins E.R. and M.C. Maiden. 2012. Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database. PLoS One 7(9): e45349.
• Whittaker R. 2013. ECDC Surveillance Report. Surveillance of invasive bacterial diseases in Europe, 2011. http://www.ecdc.europa.eu/en/publications/Publications/invasive-bacterial-diseases-surveillance-2011.pdf. 2015.01.23.
• Yamamoto K., Y. Kato, T. Shindo, M. Ujiie, N. Takeshita, S. Kanagawa, J. Kunimatsu, Y. Tamori, T. Kano, R. Okuno and others. 2013. Meningococcemia due to the 2000 Hajj-associated outbreak strain (SerogroupW-135ST-11) with immunoreactive complications. Jpn. J. Infect. Dis. 66(5): 443–445.
• Zhang X., Z. Shao, Y. Zhu, L. Xu, X. Xu, L.W. Mayer, J. Xu and Q. Jin. 2008. Genetic characteristics of serogroup A meningococci circulating in China, 1956–2005. Clin. Microbiol. Infect. 14(6): 555–561.
• Zhou J., F. Jamieson, S. Dolman, L.M. Hoang, P. Rawte and R.S. Tsang. 2012. Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15clonaltype and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009. Can. J. Infect. Dis. Med. Microbiol. 23(3): 55–59.
• Zhou H., W. Liu, L. Xu, L. Deng, Q. Deng, J. Zhuo and Z. Shao. 2013. Spread of Neisseria meningitidis serogroup W clone, China. Emerg. Infect. Dis. 19(9): 1496–1499.

Identyfikatory

DOI

10.5604/17331331.1185912